Mengmeng Chen

Mengmeng Chen

Auto-generated profile, based on publicly available information

Mengmeng Chen

Department of Internal Medicine I, University Hospital Würzburg, 97080 Würzburg, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMax Steinhardt
Max Steinhardt
VCVladimir Cejka
Vladimir Cejka
MCMengmeng Chen
Mengmeng Chen
SBSabrina Bäuerlein
Sabrina Bäuerlein
JSJulia Schäfer
Julia Schäfer
Stefan StörkStefan Störk
Stefan Störk
Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve the prognosis of patients with heart failure. Amyloidosis constitutes an important subgroup for which evidence is lacking. Amyloidotic fibrils originating from misfolded transthyretin and light chains are the causal agents in ATTR and AL amyloidosis. In these most frequent subtypes, cardiac involvement is the most common organ manifestation. Because cardiac and renal function frequently deteriorate over time, even under best available treatment, SGLT2i emerge as a promising treatment option due to their reno- and cardioprotective properties. We retrospectively analyzed patients with cardiac amyloidosis, who received either dapagliflozin or empagliflozin. Out of 79 patients, 5.1% had urinary tract infections; 2 stopped SGLT2i therapy; and 2.5% died unrelated to the intake of SGLT2i. No genital mycotic infections were observed. As expected, a slight drop in the glomerular filtration rate was noted, while the NYHA functional status, cardiac and hepatic function, as well as the 6 min walk distance remained stable over time. These data provide a rationale for the use of SGLT2i in patients with amyloidosis and concomitant cardiac or renal dysfunction. Prospective randomized data are desired to confirm safety and to prove efficacy in this increasingly important group of patients.

2 May 2024
Verified
Conference Paper
Closed access
VCVladimir Cejka
Vladimir Cejka
CHClemens Hosp
Clemens Hosp
MSMax Steinhardt
Max Steinhardt
APAikaterini Papagianni
Aikaterini Papagianni
SISandra Ihne
Sandra Ihne
CMCaroline Morbach
Caroline Morbach
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER